

Prevalence of type 2 diabetes with stable coronary artery disease but without prior myocardial infarction or stroke and THEMIS-like patients from the SNDS French nationwide claims database

P. Blin¹, P. Darmon², P. Henry³, E. Guiard¹, M-A. Bernard¹, C. Dureau-Pournin¹, H. Maizi¹, F. Thomas-Delecourt⁴, R. Lassalle¹, C. Droz-Perroteau¹, N. Moore¹

¹Bordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux, Bordeaux, France – ²Hôpital La Conception, Marseille, France – ³Hôpital Lariboisière, Paris, France – ⁴AstraZeneca, Courbevois, France

Purpose

- The THEMIS randomized trial showed a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding in ticagrelor plus aspirin group than in placebo plus aspirin group in patients with stable coronary artery disease and type 2 diabetes (CAD-T2M) without prior myocardial infarction (MI) or stroke (Steg *et al*, NEJM 2019).
- In current practice, the number of patients concerned and their characteristics are not well known.
- The main objective of this study was to assess the characteristics of CAD-T2DM adults without prior MI-stroke and, more specifically, of THEMIS-like patients in a real world setting.

Methods

- Design:** Cohort study in the French nationwide claims database (SNDS, 86% of the 66 million people).
- Data source:** The SNDS contains individual pseudonymised information from birth to death and includes out and inpatients information (drug dispensing, hospital discharge summaries, date of death...).
- Study populations:**
 - CAD-T2DM population without prior MI-stroke:** all CAD-T2DM prevalent patients without MI-stroke within the 5-year history period identified on 1st January 2014, and followed for 2 years or until death in the database.
 - THEMIS-like population:** all patients of the previous population with specific criteria (≥ 50 years at index date, without renal failure with dialysis, cirrhosis/liver cancer history, intracranial/gastro-intestinal bleeding for the last 6 months, or anticoagulant/antiplatelet agent 2 months around the index date).
- Data analysis (for both populations):**
 - Description of baseline characteristics and clinical history,
 - Estimate of the prevalence proportion on 01/01/2014 with gender and 5-year age classes standardisation according to national (INSEE) and European (Eurostat) statistics.

This study was funded by an unrestricted grant from AstraZeneca. It was designed, conducted, and analysed independently by the Bordeaux PharmacoEpi of the Bordeaux University. It was overseen by independent experts.

Results

Selection of the study populations (Figure 1)




Figure 1. Identification and selection of the study populations

Baseline characteristics (Table 1)

Table 1. Description of patient baseline characteristics

	CAD-T2DM population without prior MI-stroke n=258 260	THEMIS-like population n = 64 334
Male, n (%)	176 407 (68.3)	42 238 (65.7)
Median age (in years)	73.0	72.0
History of both CAD and T2DM diagnoses in years in categories, n (%)		
≤ 1	33 280 (12.9)	7 460 (11.6)
[1-2]	32 788 (12.7)	8 677 (13.5)
[2-3]	33 295 (12.9)	9 021 (14.0)
[3-4]	37 258 (14.4)	9 614 (14.9)
>4	67 040 (26.0)	16 346 (25.4)
Revascularisation procedure (PCI or CABG), n (%)	73 101 (28.3)	11 957 (18.6)

Clinical history (Table 2)

Table 2. Description of clinical history in study populations

	CAD-T2DM population without prior MI-stroke n = 258 260	THEMIS-like Population n = 64 334
History of major comorbidities, n (%)	229 299 (88.8)	54 390 (84.5)
Hypertension	204 943 (79.4)	48 554 (75.5)
Atrial fibrillation	55 155 (21.4)	6 647 (10.3)
Renal impairment	51 647 (20.0)	2 943 (4.6)
Peripheral arterial disease	49 703 (19.2)	7 326 (11.4)
Dyslipidemia	49 406 (19.1)	10 673 (16.6)
Cancer	47 066 (18.2)	10 958 (17.0)
Heart failure	41 744 (16.2)	5 821 (9.0)
History of diabetic complications, n (%)	101 419 (39.3)	20 301 (31.6)
Diabetic foot ulcer	68 149 (26.4)	13 506 (20.8)
Diabetic nephropathy	33 126 (32.7)	4 299 (21.2)
Diabetic retinopathy	27 715 (27.3)	5 400 (26.6)
Diabetic neuropathy	25 891 (25.5)	4 874 (24.0)

French and European prevalence (Table 3)

Table 3. Estimated 2014 prevalence of study populations for French and European* adult populations

	Populations (%)					
	CAD-T2DM without prior MI-stroke			THEMIS-like		
	Men	Women	All	Men	Women	All
French adults (all) from INSEE	8.96	3.63	6.17	2.14	0.98	1.53
18-64 years	2.81	0.78	1.78	0.72	0.23	0.47
65-75 years	27.40	7.37	16.73	6.88	2.12	4.34
>75 years	40.61	16.46	25.45	8.70	4.18	5.86
European adults (all) from Eurostat	8.74	3.51	6.04	2.09	0.95	1.50
18-64 years	2.71	0.76	1.73	0.70	0.22	0.46
65-75 years	27.74	7.54	16.88	6.95	2.16	4.37
>75 years	40.54	16.20	25.38	8.71	4.11	5.84

* standardized to 2014 EU population

Conclusions

- In real world setting, CAD-T2DM population without prior MI-stroke and THEMIS-like population had similar characteristics, although noting some differences in comorbidities.
- The THEMIS-like prevalence was estimated to be 1.53% French adults, representing about a quarter of CAD-T2DM patients without prior MI-stroke, close to the European results (1.50 %).